RMC-6272, a selective third-generation bi-steric mTORC1 inhibitor, improves cardiac function in pressure overload-induced cardiac hypertrophy

Pathological remodeling in cardiomyocytes during heart failure is driven by excessive activation of mTORC1. Preclinical studies in mice demonstrated that reducing mTORC1 activity protects against cardiac dysfunction and hypertrophic remodeling. However, clinical application of current mTOR inhibitor...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Mariam Rogge, Johannes Fischer, Tobias Jakobi, Zoe Loewenthal, Parul Gupta, Lonny Jürgensen, Norbert Frey, Christoph Sandmann, Mirko Völkers
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2026-06-01
Edice:	Journal of Molecular and Cellular Cardiology Plus
Témata:	mTOR mTORC1 Cardiac hypertrophy Heart failure Heart diseases RMC-6272
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2772976126000140
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!